BioSpace News Archive

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase through many of the more than 130 National Spine and Pain Centers (NSPC) affiliated locations across the United States for patients suffering from pain associated with different forms of primary headache.

Genocea Biosciences, Inc. announced that its Board of Directors voted to wind down the Company’s ongoing operations and terminate the Company’s remaining employees except those deemed necessary to complete an orderly wind down.

Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals ( Beijing ) Co., Ltd. (“Biocytogen”), today announced that it will present two posters at the 2022 ASCO Annual Meeting, taking place in Chicago, IL and virtually from June 3-7, 2022.

EVX-101 is a clinical-stage drug candidate currently being developed as an adjunctive treatment for when first-line antidepressants alone are inadequate.

Pear Announces Health Equity Data Showing Similar Engagement with reSET-O ® Across US Geographic Regions Presented at APA Annual Meeting.

Scipher Medicine today announced that Galapagos (Euronext & NASDAQ: GLPG) has exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD) discovered by Scipher’s Spectra™ platform.

The PPD clinical research business of Thermo Fisher Scientific has been recognized as one of the best in the world for its successful enterprise learning and development programs by the Association for Talent Development (ATD), a global organization that empowers professionals to develop talent in the workplace.

Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced the successful completion of its acquisition of Antares Pharma, Inc. (" Antares ").

Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, announced today that data presented at Digestive Disease Week (DDW) 2022 show that the company’s proprietary machine learning model accurately and consistently predicts scoring of endoscopic disease severity in ulcerative colitis (UC), a common type of inflammatory bowel disease (IBD).